| 000 | 01841 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516065843.0 | ||
| 264 | 0 | _c20120501 | |
| 008 | 201205s 0 0 eng d | ||
| 022 | _a1976-3786 | ||
| 024 | 7 |
_a10.1007/s12272-011-1117-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLi, Cheng | |
| 245 | 0 | 0 |
_aEffects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein. _h[electronic resource] |
| 260 |
_bArchives of pharmacal research _cNov 2011 |
||
| 300 |
_a1965-72 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aATP Binding Cassette Transporter, Subfamily B, Member 1 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xblood |
| 650 | 0 | 4 |
_aBiotransformation _xdrug effects |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A _xgenetics |
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A Inhibitors |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aFlavanones _xadministration & dosage |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMembrane Transport Modulators _xadministration & dosage |
| 650 | 0 | 4 |
_aMetabolic Clearance Rate _xdrug effects |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aRecombinant Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTamoxifen _xanalogs & derivatives |
| 700 | 1 | _aKim, Minhee | |
| 700 | 1 | _aChoi, HongSeok | |
| 700 | 1 | _aChoi, JunShik | |
| 773 | 0 |
_tArchives of pharmacal research _gvol. 34 _gno. 11 _gp. 1965-72 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s12272-011-1117-9 _zAvailable from publisher's website |
| 999 |
_c21364819 _d21364819 |
||